Novanta Inc Cash Flow Conversion Efficiency
Novanta Inc cash flow conversion efficiency. Based on the latest financial reports, Novanta Inc (1GSN) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€8.49 Million ≈ $9.93 Million USD) by net assets (€801.48 Million ≈ $937.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Novanta Inc (2015–2024)
Cash flow conversion efficiency of Novanta Inc from 2015 to 2024. This chart illustrates how Novanta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Novanta Inc for real-time trading data and today's change.
Novanta Inc Cash Flow Conversion Ratio Explained
Novanta Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Novanta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novanta Inc ranked by their cash flow conversion efficiency. Also see 1GSN market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
|
0.014x |
|
Wuhan Jingce Electronic Technology Co Ltd
SHE:300567
|
-0.001x |
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
N/A |
|
Grupo Aeroportuario del Centro Norte SAB de CV
NASDAQ:OMAB
|
0.137x |
|
GDS Holdings Limited
F:G40
|
0.043x |
|
China Great Wall Securities Co Ltd Class A
SHE:002939
|
0.137x |
|
IOI Properties Group Bhd
KLSE:5249
|
0.011x |
|
Dexus
AU:DXS
|
0.059x |
Annual Cash Flow Conversion Efficiency for Novanta Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Novanta Inc from 2015 to 2024. Review Novanta Inc (1GSN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €745.70 Million ≈ $871.80 Million |
€158.51 Million ≈ $185.32 Million |
0.213x | +19.22% |
| 2023-12-31 | €673.46 Million ≈ $787.35 Million |
€120.08 Million ≈ $140.38 Million |
0.178x | +13.44% |
| 2022-12-31 | €577.59 Million ≈ $675.26 Million |
€90.78 Million ≈ $106.13 Million |
0.157x | -13.41% |
| 2021-12-31 | €521.29 Million ≈ $609.44 Million |
€94.62 Million ≈ $110.63 Million |
0.182x | -38.28% |
| 2020-12-31 | €476.81 Million ≈ $557.44 Million |
€140.24 Million ≈ $163.95 Million |
0.294x | +94.00% |
| 2019-12-31 | €417.17 Million ≈ $487.72 Million |
€63.25 Million ≈ $73.94 Million |
0.152x | -37.72% |
| 2018-12-31 | €368.25 Million ≈ $430.53 Million |
€89.65 Million ≈ $104.81 Million |
0.243x | +19.67% |
| 2017-12-31 | €311.55 Million ≈ $364.23 Million |
€63.38 Million ≈ $74.10 Million |
0.203x | +10.20% |
| 2016-12-31 | €258.87 Million ≈ $302.65 Million |
€47.79 Million ≈ $55.87 Million |
0.185x | +35.18% |
| 2015-12-31 | €244.70 Million ≈ $286.08 Million |
€33.42 Million ≈ $39.07 Million |
0.137x | -- |
About Novanta Inc
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets las… Read more